Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients

[1]  Y. Nakanishi,et al.  Intrinsic and Extrinsic Regulation of PD‐L2 Expression in Oncogene‐Driven Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Y. Maehara,et al.  A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. , 2017, Clinical lung cancer.

[3]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[4]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Y. Maehara,et al.  Clinical Significance of PD‐L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[7]  L. Gandhi,et al.  Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review. , 2016, JAMA oncology.

[8]  P. Jänne,et al.  Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[10]  H. Min,et al.  Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status , 2015, Modern Pathology.

[11]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[12]  Y. Jeon,et al.  Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers. , 2015, Lung cancer.

[13]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[14]  Haiquan Chen,et al.  Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma , 2014, OncoTargets and therapy.

[15]  Masahiko Kusumoto,et al.  Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. , 2013, The Journal of thoracic and cardiovascular surgery.

[16]  B. Robinson,et al.  Programmed Death Ligand 2 in Cancer-Induced Immune Suppression , 2012, Clinical & developmental immunology.

[17]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[18]  S. Hodge,et al.  Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects , 2007, Clinical and experimental immunology.

[19]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[20]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[21]  G. Freeman,et al.  Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis , 2003, European journal of immunology.

[22]  P. Loke,et al.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Pardoll,et al.  Expression of Programmed Death 1 Ligands by Murine T Cells and APC1 , 2002, The Journal of Immunology.

[24]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[25]  N. Bhattacharya,et al.  An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. , 2017, Cancer research.

[26]  A. Jemal,et al.  Global Cancer Statistics , 2011 .